Citation: Bohan Chen, Liming Gong, Jing Feng, Mingji Jin, Liqing Chen, Zhonggao Gao, Wei Huang. Research advances of nanoparticles for CAR-T therapy in solid tumors[J]. Chinese Chemical Letters, ;2024, 35(9): 109432. doi: 10.1016/j.cclet.2023.109432 shu

Research advances of nanoparticles for CAR-T therapy in solid tumors

Bohan Chen ^{a, b, c} ,
Liming Gong ^{a, b} ,
Jing Feng ^{a, b} ,
Mingji Jin ^{a, b} ,
Liqing Chen ^{a, b} ,
Zhonggao Gao ^{a, b} ,
Wei Huang ^{a, b, *,}

a.
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
b.
Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
c.
School of Pharmacy, Qingdao University, Qingdao 266071, China

huangwei@imm.ac.cn

Received Date: 9 November 2023
Revised Date: 13 December 2023
Accepted Date: 18 December 2023
Available Online: 20 December 2023

Figures(5)

As one of the most promising adoptive T-cell therapies, chimeric antigen receptor T-cell (CAR-T) therapy has acquired Food and Drug Administration (FDA) approval for a variety of products and has been used successfully in the treatment of malignant hematological tumors. CAR-T therapy, on the other hand, faces a number of obstacles in the field of solid tumor therapy that limit its widespread clinical implementation. Significant advances in nanoparticle research in cancer therapy and immunotherapy have been made in recent years, providing novel strategies to address the challenges encountered by CAR-T therapy in the treatment of solid tumors. This review commences with a comprehensive explanation of the basic framework of CAR-T therapy as well as the challenges it faces in the treatment of solid tumors. Subsequently, we encapsulate a summary of the developmental research combining nanoparticles with CAR-T cells for the treatment of solid tumors, which includes gene transfection, cell activation and expansion, targeted infiltration, immune escape inhibition, and combination with other therapies. Coupled with the overview of the research progress, a discussion has been initiated on the challenges and perspectives of CAR-T based on nanoparticles.
- CAR-T therapy,
- Nanoparticles,
- Solid tumors,
- Immunotherapy,
- T cell
1. [1]
  R.S. Riley, C.H. June, R. Langer, M.J. Mitchell, Nat. Rev. Drug Discov. 18 (2019) 175–196. doi: 10.1038/s41573-018-0006-z
2. [2]
  N. Hashemzadeh, M. Dolatkhah, K. Adibkia, et al., Life Sci. 271 (2021) 119110. doi: 10.1016/j.lfs.2021.119110
3. [3]
  E.N. Baruch, A.L. Berg, M.J. Besser, et al., Cancer 123 (2017) 2154–2162. doi: 10.1002/cncr.30491
4. [4]
  E. Bockamp, S. Rosigkeit, D. Siegl, D. Schuppan, Cells 9 (2020) 2102. doi: 10.3390/cells9092102
5. [5]
  Y. Ping, C. Liu, Y. Zhang, Protein Cell 9 (2018) 254–266. doi: 10.1007/s13238-016-0367-1
6. [6]
  T. Haslauer, R. Greil, N. Zaborsky, R. Geisberger, Int. J. Mol. Sci. 22 (2021) 8996. doi: 10.3390/ijms22168996
7. [7]
  N. Watanabe, F. Mo, M.K. McKenna, Front. Immunol. 13 (2022) 876339. doi: 10.3389/fimmu.2022.876339
8. [8]
  Z. Ying, H. Yang, Y. Guo, et al., Cancer Med. 10 (2021) 999–1011. doi: 10.1002/cam4.3686
9. [9]
  P.B. Balakrishnan, E.E. Sweeney, Front. Immunol. 12 (2021) 600659. doi: 10.3389/fimmu.2021.600659
10. [10]
  M. Martinez, E.K. Moon, Front. Immunol. 10 (2019) 128. doi: 10.3389/fimmu.2019.00128
11. [11]
  S. Yu, A. Li, Q. Liu, et al., J. Hematol. Oncol. 10 (2017) 78. doi: 10.1016/j.dsi.2017.02.004
12. [12]
  C. Qi, J. Gong, J. Li, et al., Nat. Med. 28 (2022) 1189–1198. doi: 10.1038/s41591-022-01800-8
13. [13]
  P.S. Adusumilli, M.G. Zauderer, I. Rivière, et al., Cancer Discov. 11 (2021) 2748–2763. doi: 10.1158/2159-8290.cd-21-0407
14. [14]
  V. Narayan, J.S. Barber-Rotenberg, I.Y. Jung, et al., Nat. Med. 28 (2022) 724–734. doi: 10.1038/s41591-022-01726-1
15. [15]
  R.G. Majzner, S. Ramakrishna, K.W. Yeom, et al., Nature 603 (2022) 934–941. doi: 10.1038/s41586-022-04489-4
16. [16]
  N. Pang, J. Shi, L. Qin, et al., J. Hematol. Oncol. 14 (2021) 118. doi: 10.1186/s13045-021-01128-9
17. [17]
  Y. Zhang, Z. Zhang, Y. Ding, et al., J. Cancer Res. Clin. Oncol. 147 (2021) 3725–3734. doi: 10.1007/s00432-021-03613-7
18. [18]
  P.D. Shah, A.C. Huang, X. Xu, et al., Cancer Res. Commun. 3 (2023) 821–829. doi: 10.1158/2767-9764.crc-22-0486
19. [19]
  N.A. Vitanza, A.J. Johnson, A.L. Wilson, et al., Nat. Med. 27 (2021) 1544–1552. doi: 10.1038/s41591-021-01404-8
20. [20]
  Z. Wang, N. Li, K. Feng, et al., Cell Mol. Immunol. 18 (2021) 2188–2198. doi: 10.1038/s41423-021-00749-x
21. [21]
  I. Rana, J. Oh, J. Baig, et al., Drug Deliv. Transl. Res. 13 (2022) 1936–1954.
22. [22]
  H. Heping, Y. Lijia, D. Zhao, et al., Chin. Chem. Lett. 34 (2023) 108592. doi: 10.1016/j.cclet.2023.108592
23. [23]
  Z. Zheng, S. Li, M. Liu, et al., Cancers 15 (2023) 3476. doi: 10.3390/cancers15133476
24. [24]
  S. Thomas, H. Abken, Front. Immunol. 13 (2022) 1090959.
25. [25]
  J. Lu, G. Jiang, Mol. Cancer 21 (2022) 194. doi: 10.1186/s12943-022-01663-0
26. [26]
  E. Chrusciel, Z. Urban-Wojciuk, L. Arcimowicz, et al., Cancers (Basel) 12 (2020) 683. doi: 10.3390/cancers12030683
27. [27]
  E. Leon, R. Ranganathan, B. Savoldo, Semin. Immunol. 49 (2020) 101437. doi: 10.1016/j.smim.2020.101437
28. [28]
  S. He, S. Li, J. Guo, et al., Transl. Oncol. 27 (2023) 101575. doi: 10.1016/j.tranon.2022.101575
29. [29]
  M. Yang, X. Tang, Z. Zhang, et al., Theranostics 10 (2020) 7622–7634. doi: 10.7150/thno.43991
30. [30]
  O. Harush, N. Asherie, S. Kfir-Erenfeld, et al., Haematologica 107 (2022) 2395–2407. doi: 10.3324/haematol.2021.280169
31. [31]
  A. Bister, T. Ibach, C. Haist, et al., Mol. Ther. Oncolytics 26 (2022) 120–134. doi: 10.1016/j.omto.2022.05.012
32. [32]
  G. Dagar, A. Gupta, T. Masoodi, et al., J. Transl. Med. 21 (2023) 449. doi: 10.1186/s12967-023-04292-3
33. [33]
  N. Li, A. Quan, D. Li, et al., Nat. Commun. 14 (2023) 1986. doi: 10.1038/s41467-023-37616-4
34. [34]
  E. Schoutrop, T. Poiret, I. El-Serafi, et al., J. Immunother. Cancer 11 (2023) e005691. doi: 10.1136/jitc-2022-005691
35. [35]
  N. Xie, G. Shen, W. Gao, et al., Signal Transduct. Target. Ther. 8 (2023) 9. doi: 10.1038/s41392-022-01270-x
36. [36]
  M.H. Shin, E. Oh, Y. Kim, et al., Cells 12 (2023) 1606. doi: 10.3390/cells12121606
37. [37]
  T. Tokatlian, G.E. Asuelime, J.Y. Mock, et al., J. Immunother. Cancer 10 (2022) e003826. doi: 10.1136/jitc-2021-003826
38. [38]
  K. Feng, Y. Liu, Y. Guo, et al., Protein Cell 9 (2018) 838–847. doi: 10.1007/s13238-017-0440-4
39. [39]
  Y. Guo, K. Feng, Y. Liu, et al., Clin. Cancer Res. 24 (2018) 1277–1286. doi: 10.1158/1078-0432.ccr-17-0432
40. [40]
  R.L. Gomez, S. Ibragimova, R. Ramachandran, et al., Biochim. Biophys. Acta Rev. Cancer 1877 (2022) 188805. doi: 10.1016/j.bbcan.2022.188805
41. [41]
  A. Johnson, M. Townsend, K. O'Neill, Cells 11 (2022) 3626. doi: 10.3390/cells11223626
42. [42]
  M. Hamieh, J. Mansilla-Soto, I. Rivière, M. Sadelain, Cancer Discov. 13 (2023) 829–843. doi: 10.1158/2159-8290.cd-23-0101
43. [43]
  A.E. Andrea, A. Chiron, S. Mallah, et al., Front. Immunol. 13 (2022) 830292. doi: 10.3389/fimmu.2022.830292
44. [44]
  E. Donnadieu, L. Dupré, L.G. Pinho, V. Cotta-de-Almeida, J. Leukoc. Biol. 108 (2020) 1067–1079. doi: 10.1002/jlb.1mr0520-746r
45. [45]
  Y. Xie, X. Li, J. Wu, et al., Chin. Chem. Lett. 34 (2023) 108202. doi: 10.1016/j.cclet.2023.108202
46. [46]
  W. Jing, W. Yanran, C. Tianyou, H. Chunxia, Chin. Chem. Lett. 33 (2022) 1180–1192. doi: 10.1016/j.cclet.2021.07.067
47. [47]
  K. Kheyrolahzadeh, M.R. Tohidkia, A. Tarighatnia, et al., Life Sci. 328 (2023) 121917. doi: 10.1016/j.lfs.2023.121917
48. [48]
  H. Wang, S.T. Tsao, M. Gu, et al., J. Transl. Med. 20 (2022) 608. doi: 10.3390/met12040608
49. [49]
  E.S. Atsavapranee, M.M. Billingsley, M.J. Mitchell, EBioMedicine 67 (2021) 103354. doi: 10.1016/j.ebiom.2021.103354
50. [50]
  J.C.K. Tay, J. Wang, Z. Du, et al., Mol. Ther. Methods Clin. Dev. 21 (2021) 107–120. doi: 10.1016/j.omtm.2021.02.023
51. [51]
  M. Sainz-Ramos, I. Gallego, I. Villate-Beitia, et al., Int. J. Mol. Sci. 22 (2021) 7545. doi: 10.3390/ijms22147545
52. [52]
  Y. Liu, C. Li, Y. Lu, et al., Front. Immunol. 13 (2022) 1016817. doi: 10.3389/fimmu.2022.1016817
53. [53]
  A. Aghanejad, S.F. Bonab, M. Sepehri, et al., Int. J. Biol. Macromol. 207 (2022) 592–610. doi: 10.1016/j.ijbiomac.2022.03.057
54. [54]
  C. Chen, Z. Wang, Y. Ding, Y. Qin, Front. Immunol. 14 (2023) 1133308. doi: 10.3389/fimmu.2023.1133308
55. [55]
  Z. Xu, Y. Chen, L. Ma, et al., Mol. Ther. 30 (2022) 3133–3154. doi: 10.1016/j.ymthe.2022.01.046
56. [56]
  Z. Yuan, Y. Li, S. Zhang, et al., Mol. Cancer 22 (2023) 48. doi: 10.1186/s12943-023-01744-8
57. [57]
  E.J. Wherry, M. Kurachi, Nat. Rev. Immunol. 15 (2015) 486–499. doi: 10.1038/nri3862
58. [58]
  D. Fan, Y. Cao, M. Cao, et al., Signal Transduct. Target. Ther. 8 (2023) 293. doi: 10.1038/s41392-023-01536-y
59. [59]
  W. Yang, J. Cao, H. Cheng, et al., Bioact. Mater. 23 (2023) 438–470. doi: 10.3390/separations10080438
60. [60]
  R.P. Labbé, S. Vessillier, Q.A. Rafiq, Viruses 13 (2021) 1528. doi: 10.3390/v13081528
61. [61]
  M. Ruella, J. Xu, D.M. Barrett, et al., Nat. Med. 24 (2018) 1499–1503. doi: 10.1038/s41591-018-0201-9
62. [62]
  R.A. Morgan, J.C. Yang, M. Kitano, et al., Mol. Ther. 18 (2010) 843–851. doi: 10.1038/mt.2010.24
63. [63]
  R. Mohanty, C.R. Chowdhury, S. Arega, et al., Oncol. Rep. 42 (2019) 2183–2195.
64. [64]
  N. Sandoval-Villegas, W. Nurieva, M. Amberger, Z. Ivics, Int. J. Mol. Sci. 22 (2021) 5084. doi: 10.3390/ijms22105084
65. [65]
  V. Jayasooriya, B. Ringwelski, G. Dorsam, D. Nawarathna, Lab Chip 21 (2021) 3748–3761. doi: 10.1039/d1lc00219h
66. [66]
  H.J. Vaughan, J.J. Green, S.Y. Tzeng, Adv. Mater. 32 (2020) e1901081. doi: 10.1002/adma.201901081
67. [67]
  Q. Zeng, Z. Liu, T. Niu, et al., Chin. Chem. Lett. 34 (2023) 107747. doi: 10.1016/j.cclet.2022.107747
68. [68]
  J. Fan, Q. He, Z. Jin, et al., RSC Adv. 8 (2018) 14975–14982. doi: 10.1039/c8ra02133c
69. [69]
  Y. Xi, C. Qixian, W. Jingyun, et al., Chin. Chem. Lett. 31 (2020) 3143–3148. doi: 10.1016/j.cclet.2020.07.027
70. [70]
  T.T. Smith, S.B. Stephan, H.F. Moffett, et al., Nat. Nanotechnol. 12 (2017) 813–820. doi: 10.1038/nnano.2017.57
71. [71]
  P.P.G. Guimaraes, R. Zhang, R. Spektor, et al., J. Control. Rel. 316 (2019) 404–417. doi: 10.1016/j.jconrel.2019.10.028
72. [72]
  J.G. Rurik, I. Tombácz, A. Yadegari, et al., Science 375 (2022) 91–96. doi: 10.1126/science.abm0594
73. [73]
  X. Liu, Y. Zhang, S. Zhou, et al., J. Control. Release 348 (2022) 84–94. doi: 10.1016/j.jconrel.2022.05.043
74. [74]
  H. Li, K. Peng, K. Yang, et al., Theranostics 12 (2022) 6422–6436. doi: 10.7150/thno.77350
75. [75]
  M.M. Billingsley, N. Singh, P. Ravikumar, et al., Nano Lett. 20 (2020) 1578–1589. doi: 10.1021/acs.nanolett.9b04246
76. [76]
  L. Raes, S. Stremersch, J.C. Fraire, et al., Nanomicro Lett. 12 (2020) 185.
77. [77]
  D. Kalamasz, S.A. Long, R. Taniguchi, et al., J. Immunother. 27 (2004) 405–418. doi: 10.1097/00002371-200409000-00010
78. [78]
  E.R. Steenblock, S.H. Wrzesinski, R.A. Flavell, T.M. Fahmy, Expert Opin. Biol. Ther. 9 (2009) 451–464. doi: 10.1517/14712590902849216
79. [79]
  J. Matic, J. Deeg, A. Scheffold, et al., Nano Lett. 13 (2013) 5090–5097. doi: 10.1021/nl4022623
80. [80]
  J. Guasch, C.A. Muth, J. Diemer, et al., Nano Lett. 17 (2017) 6110–6116. doi: 10.1021/acs.nanolett.7b02636
81. [81]
  J. Guasch, M. Hoffmann, J. Diemer, et al., Nano Lett. 18 (2018) 5899–5904.
82. [82]
  L. Tang, Y. Zheng, M.B. Melo, et al., Nat. Biotechnol. 36 (2018) 707–716. doi: 10.1038/nbt.4181
83. [83]
  L.R. Neal, S.R. Bailey, M.M. Wyatt, et al., J. Immunol. Res. Ther. 2 (2017) 68–79.
84. [84]
  K. Perica, J.G. Bieler, C. Schütz, et al., ACS Nano 9 (2015) 6861–6871. doi: 10.1021/acsnano.5b02829
85. [85]
  J.W. Hickey, A. Isser, S.F. Salathe, et al., Nano Lett. 20 (2020) 6289–6298. doi: 10.1021/acs.nanolett.0c01511
86. [86]
  A. Isser, A.B. Silver, H.C. Pruitt, et al., Nat. Commun. 13 (2022) 6086. doi: 10.1038/s41467-022-33597-y
87. [87]
  L. Ma, T. Dichwalkar, J.Y.H. Chang, et al., Science 365 (2019) 162–168. doi: 10.1126/science.aav8692
88. [88]
  H. Bo, K. Sudong, W. Yuhua, et al., Chin. Chem. Lett. 34 (2023) 108210. doi: 10.1016/j.cclet.2023.108210
89. [89]
  H. Zang, M. Siddiqui, S. Gummuluru, et al., ACS Nano 16 (2022) 18408–18420. doi: 10.1021/acsnano.2c06516
90. [90]
  S. Jie, Z. Zhifang, H. Haofei, et al., Chin. Chem. Lett. 32 (2021) 4041–4044. doi: 10.1016/j.cclet.2021.04.034
91. [91]
  P.S. Adusumilli, L. Cherkassky, J. Villena-Vargas, et al., Sci. Transl. Med. 6 (2014) 261ra151.
92. [92]
  C. Zheng, J. Zhang, H.F. Chan, et al., Small Methods 5 (2021) e2001191. doi: 10.1002/smtd.202001191
93. [93]
  E.S. Jang, J.H. Shin, G. Ren, et al., Biomaterials 33 (2012) 5584–5592. doi: 10.1016/j.biomaterials.2012.04.041
94. [94]
  L. Sanz-Ortega, Y. Portilla, S. Pérez-Yagüe, D.F. Barber, J. Nanobiotechnol. 17 (2019) 87. doi: 10.1186/s12951-019-0520-0
95. [95]
  W. Nie, W. Wei, L. Zuo, et al., ACS Nano 13 (2019) 1469–1478. doi: 10.1021/acsnano.8b07141
96. [96]
  N.T. Nguyen, K. Huang, H. Zeng, et al., Nat. Nanotechnol. 16 (2021) 1424–1434. doi: 10.1038/s41565-021-00982-5
97. [97]
  H. Tang, J. Qiao, Y.X. Fu, Cancer Lett. 370 (2016) 85–90. doi: 10.1016/j.canlet.2015.10.009
98. [98]
  K.G. Nguyen, M.R. Vrabel, S.M. Mantooth, et al., Front. Immunol. 11 (2020) 575597. doi: 10.3389/fimmu.2020.575597
99. [99]
  Y. Liu, K. Adu-Berchie, J.M. Brockman, et al., Proc. Natl. Acad. Sci. U.S.A. 120 (2023) e2213222120. doi: 10.1073/pnas.2213222120
100. [100]
  M. Davoodzadeh Gholami, G.A. Kardar, Y. Saeedi, et al., Cell Immunol. 322 (2017) 1–14. doi: 10.1016/j.cellimm.2017.10.002
101. [101]
  E.K. Moon, L.C. Wang, D.V. Dolfi, et al., Clin. Cancer Res. 20 (2014) 4262–4273. doi: 10.1158/1078-0432.CCR-13-2627
102. [102]
  Z. Guo, X. Wang, D. Cheng, et al., PLoS ONE 9 (2014) e89350. doi: 10.1371/journal.pone.0089350
103. [103]
  A. Heczey, C.U. Louis, B. Savoldo, et al., Mol. Ther. 25 (2017) 2214–2224. doi: 10.1016/j.ymthe.2017.05.012
104. [104]
  R.Y. Huang, A. Francois, A.R. McGray, et al., Oncoimmunology 6 (2017) e1249561. doi: 10.1080/2162402X.2016.1249561
105. [105]
  F. Zhang, S.B. Stephan, C.I. Ene, et al., Cancer Res. 78 (2018) 3718–3730. doi: 10.1158/0008-5472.can-18-0306
106. [106]
  H. Yingying, C. Xuesi, T. Huayu, et al., Chin. Chem. Lett. 32 (2021) 1770–1774. doi: 10.1016/j.cclet.2020.12.055
107. [107]
  L.K. Hong, Y. Chen, C.C. Smith, et al., Cancer Immunol. Res. 6 (2018) 1274–1287. doi: 10.1158/2326-6066.cir-18-0065
108. [108]
  J.F. Modiano, D. Bellgrau, Discov. Med. 21 (2016) 109–116.
109. [109]
  R. Upadhyay, J.A. Boiarsky, G. Pantsulaia, et al., Cancer Discov. 11 (2021) 599–613. doi: 10.1158/2159-8290.cd-20-0756
110. [110]
  D. Hanahan, R.A. Weinberg, Cell 100 (2000) 57–70. doi: 10.1016/S0092-8674(00)81683-9
111. [111]
  Z.Y. Al Subeh, D.B. Poschel, P.S. Redd, et al., ACS Nano 16 (2022) 12695–12710. doi: 10.1021/acsnano.2c04420
112. [112]
  P.A. Beavis, M.A. Henderson, L. Giuffrida, et al., J. Clin. Invest. 127 (2017) 929–941. doi: 10.1172/JCI89455
113. [113]
  N. Siriwon, Y.J. Kim, E. Siegler, et al., Cancer Immunol. Res. 6 (2018) 812–824. doi: 10.1158/2326-6066.cir-17-0502
114. [114]
  A. Tiwari, R. Trivedi, S.Y. Lin, J. Biomed. Sci. 29 (2022) 83. doi: 10.1186/s12929-022-00866-3
115. [115]
  L. Yanan, C. Jing, L. Chenlong, et al., Chin. Chem. Lett. 34 (2023) 108180. doi: 10.1016/j.cclet.2023.108180
116. [116]
  Z. Chen, H. Pan, Y. Luo, et al., Small 17 (2021) e2007494. doi: 10.1002/smll.202007494
117. [117]
  J. Ning, L. Rongtao, X. Wei, et al., Chin. Chem. Lett. 32 (2021) 3948–3953. doi: 10.1016/j.cclet.2021.06.053
118. [118]
  L. Zhu, J. Liu, G. Zhou, et al., Small 17 (2021) e2102624. doi: 10.1002/smll.202102624
119. [119]
  N.E. Sounni, K. Dehne, L. van Kempen, et al., Dis. Model. Mech. 3 (2010) 317–332. doi: 10.1242/dmm.003863
120. [120]
  C.L. Day, D.E. Kaufmann, P. Kiepiela, et al., Nature 443 (2006) 350–354. doi: 10.1038/nature05115
121. [121]
  Y. Tang, W. Yao, H. Hang, et al., Mater. Today Bio. 20 (2023) 100615. doi: 10.1016/j.mtbio.2023.100615
122. [122]
  W. Ma, D. Zhu, J. Li, et al., Theranostics 10 (2020) 1281–1295. doi: 10.7150/thno.40291
123. [123]
  H. Li, X. Yang, Z. Wang, et al., ACS Nano 17 (2023) 11749–11763. doi: 10.1021/acsnano.3c02592
124. [124]
  Y.J. Chen, B. Abila, Y.Mostafa Kamel, Cancers (Basel) 15 (2023) 663. doi: 10.3390/cancers15030663
125. [125]
  Y. Liu, N. Li, W. Jiang, Q. Geng, Chin. J. Lung Cancer 26 (2023) 59–65.
126. [126]
  M. Durai, C. Krueger, Z. Ye, et al., Cancer Immunol. Immunother. 58 (2009) 209–220. doi: 10.1007/s00262-008-0542-1
1. [1]
  Shuang Liang , Jianjun Yao , Dan Liu , Mengli Zhou , Yong Cui , Zhaohui Wang . Tumor-responsive covalent organic polymeric nanoparticles enhancing STING activation for cancer immunotherapy. Chinese Chemical Letters, 2025, 36(3): 109856-. doi: 10.1016/j.cclet.2024.109856
2. [2]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
3. [3]
  Wei Su , Xiaoyan Luo , Peiyuan Li , Ying Zhang , Chenxiang Lin , Kang Wang , Jianzhuang Jiang . Phthalocyanine self-assembled nanoparticles for type Ⅰ photodynamic antibacterial therapy. Chinese Chemical Letters, 2024, 35(12): 109522-. doi: 10.1016/j.cclet.2024.109522
4. [4]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
5. [5]
  Yuwen Zhu , Xiang Deng , Yan Wu , Baode Shen , Lingyu Hang , Yuye Xue , Hailong Yuan . Formation mechanism of herpetrione self-assembled nanoparticles based on pH-driven method. Chinese Chemical Letters, 2025, 36(1): 109733-. doi: 10.1016/j.cclet.2024.109733
6. [6]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
7. [7]
  Yihao Zhang , Yang Jiao , Xianchao Jia , Qiaojia Guo , Chunying Duan . Highly effective self-assembled porphyrin MOCs nanomaterials for enhanced photodynamic therapy in tumor. Chinese Chemical Letters, 2024, 35(5): 108748-. doi: 10.1016/j.cclet.2023.108748
8. [8]
  Yuequan Wang , Congtian Wu , Chengcheng Feng , Qin Chen , Zhonggui He , Shenwu Zhang , Cong Luo , Jin Sun . Spatiotemporally-controlled supramolecular hybrid nanoassembly enabling ferroptosis-augmented photodynamic immunotherapy of cancer. Chinese Chemical Letters, 2025, 36(3): 109902-. doi: 10.1016/j.cclet.2024.109902
9. [9]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
10. [10]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
11. [11]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
12. [12]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
13. [13]
  Yixin Zhang , Ting Wang , Jixiang Zhang , Pengyu Lu , Neng Shi , Liqiang Zhang , Weiran Zhu , Nongyue He . Formation mechanism for stable system of nanoparticle/protein corona and phospholipid membrane. Chinese Chemical Letters, 2024, 35(4): 108619-. doi: 10.1016/j.cclet.2023.108619
14. [14]
  Keyang Li , Yanan Wang , Yatao Xu , Guohua Shi , Sixian Wei , Xue Zhang , Baomei Zhang , Qiang Jia , Huanhua Xu , Liangmin Yu , Jun Wu , Zhiyu He . Flash nanocomplexation (FNC): A new microvolume mixing method for nanomedicine formulation. Chinese Chemical Letters, 2024, 35(10): 109511-. doi: 10.1016/j.cclet.2024.109511
15. [15]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
16. [16]
  Fereshte Hassanzadeh-Afruzi , Mina Azizi , Iman Zare , Ehsan Nazarzadeh Zare , Anwarul Hasan , Siavash Iravani , Pooyan Makvandi , Yi Xu . Advanced metal-organic frameworks-polymer platforms for accelerated dermal wound healing. Chinese Chemical Letters, 2024, 35(11): 109564-. doi: 10.1016/j.cclet.2024.109564
17. [17]
  Shenglan Zhou , Haijian Li , Hongyi Gao , Ang Li , Tian Li , Shanshan Cheng , Jingjing Wang , Jitti Kasemchainan , Jianhua Yi , Fengqi Zhao , Wengang Qu . Recent advances in metal-loaded MOFs photocatalysts: From single atom, cluster to nanoparticle. Chinese Chemical Letters, 2025, 36(1): 110142-. doi: 10.1016/j.cclet.2024.110142
18. [18]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
19. [19]
  Shuyu Liu , Xiaomin Sun , Bohan Song , Gaofeng Zeng , Bingbing Du , Chongshen Guo , Cong Wang , Lei Wang . Design and Fabrication of Phospholipid-Vesicle-based Artificial Cells towards Biomedical Applications. University Chemistry, 2024, 39(11): 182-188. doi: 10.12461/PKU.DXHX202404113
20. [20]
  Jisheng Liu , Junli Chen , Xifeng Zhang , Yin Wu , Xin Qi , Jie Wang , Xiang Gao . Red blood cell membrane-coated FLT3 inhibitor nanoparticles to enhance FLT3-ITD acute myeloid leukemia treatment. Chinese Chemical Letters, 2024, 35(9): 109779-. doi: 10.1016/j.cclet.2024.109779

Get Citation

PDF

XML

Metrics

PDF Downloads(3)
Abstract views(528)
HTML views(15)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142